Krka Pharmaceuticals is Europe’s seventh largest generic drug producer with 2.4 billion Euros as its market capitalization. The said company is Slovenia’s largest company which is planning to remain independent. Furthermore, according to their Chief Executive Mr. Joza Colaric, they are also planning to takeover some companies within Europe and are pursuing in doubling the investments this 2010. This hasn’t been confirmed if it will take part this year yet remained a possibility for the company’s goal of expanding their business.

To further expand their capacity of producing different drugs, the company plans of taking over small or perhaps medium sized companies. With this step, Krka can be able to produce new products as well as open new markets. With this market plan, they are expecting a rise in their sales from 6 percent which is about 1 billion Euros though their previous post states only a 0.1 percent growth in the year 2009 due to currency losses. Krka Pharmaceuticals have been mainly affected with the decreasing local currencies from the countries Ukraine, Russia as well as Poland.

The company is anticipating a triple production within the next three year from its Moscow factory which will be their major investment this year. The said investment will be financed mainly from the company’s cash plus bank loans wherein they still have good access. Plus, the said company also plans to increase their employees from in the years to come.